Florida Senate SB 518 By Senator Saunders

Similar documents
IC Chapter 19. Drugs: Indiana Legend Drug Act

PRESCRIPTION MONITORING PROGRAM MODEL ACT 2010 Revision

GENERIC EQUIVALENT DRUG LAW Act of Nov. 24, 1976, P.L. 1163, No. 259 AN ACT Relating to the prescribing and dispensing of generic equivalent drugs.

State Prescription Fraud Provisions

CHAPTER Committee Substitute for House Bill No. 4043

CODING: Words stricken are deletions; words underlined are additions. hb c1

CODING: Words stricken are deletions; words underlined are additions. hb e1

HOUSE AMENDMENT Bill No. HB 5511 (2012) Amendment No. CHAMBER ACTION

CHAPTER House Bill No. 5511

HP0557, LD 821, item 2, 124th Maine State Legislature, Amendment C "A", Filing Number H-625, Sponsored by

CHAPTER 53 PHARMACY AND POISONS ORDINANCE ARRANGEMENT OF SECTIONS PART I PRELIMINARY PART II PHARMACY

State Control of Dextromethorphan (a.k.a. DXM): Summary

Assembly Bill No. 602 CHAPTER 139

SAFE IMPORTATION OF MEDICAL PRODUCTS AND OTHER RX THERAPIES ACT OF 2004 (SAFE IMPORT ACT) SECTION-BY-SECTION SEC. 1. SHORT TITLE.

Federal Register / Vol. 75, No. 193 / Wednesday, October 6, 2010 / Rules and Regulations

POCKET REFERENCE DRUG SAMPLE DISTRIBUTION: SELECT FEDERAL LAWS AND REGULATIONS

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 640

REPUBLIC OF SOUTH AFRICA

- 79th Session (2017) Assembly Bill No. 474 Committee on Health and Human Services

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 HOUSE BILL DRH10229-MG-122A (03/23) Short Title: End of Life Option Act. (Public)

CHAPTER House Bill No. 1113

CHAPTER Senate Bill No. 2510

874 October 9, 2013 No. 380 IN THE COURT OF APPEALS OF THE STATE OF OREGON. STATE OF OREGON, Plaintiff-Respondent,

BERMUDA PHARMACY AND POISONS ACT : 26

State Control of Dextromethorphan (a.k.a. DXM) Statutory Text

Senate Bill No. 310 Senator Carlton

CHAPTER House Bill No. 7023

8 SYNOPSIS: Under existing law, a capital defendant may. 9 be executed by lethal injection or electrocution,

Citation to Code of Federal Regulations and statutory citation (as applicable):

A Bill Regular Session, 2017 SENATE BILL 339

CHAPTER House Bill No. 7025

John R. McPherson, DDS, Secretary/Treasurer. Brenda Upton, RPh, Board Member Governor: Matthew H. Mead

THE PRIVACY ACT OF 1974 (As Amended) Public Law , as codified at 5 U.S.C. 552a

compounded or made by or under the direct and personal supervision of a

CHAPTER Committee Substitute for Committee Substitute for Committee Substitute for House Bill No. 993 and House Bill No.

ARTICLE XIV PAIN MANAGEMENT CLINICS AND CASH ONLY PHARMACIES

Section moves to amend H.F. No as follows: 1.2 Delete everything after the enacting clause and insert:

CHAPTER House Bill No. 693

CHAPTER Committee Substitute for House Bill No. 765

CHAPTER 36. MEDICAID FRAUD PREVENTION SUBCHAPTER A. GENERAL PROVISIONS

Supreme Court of Florida

Recommendation to Adopt Proposed Ordinance Relating to Pain Management Clinics

NC General Statutes - Chapter 163 Article 20 1

HOUSE OF REPRESENTATIVES STAFF ANALYSIS REFERENCE ACTION ANALYST STAFF DIRECTOR

SENATE, No STATE OF NEW JERSEY. 215th LEGISLATURE INTRODUCED AUGUST 19, 2013

COLLEGE OF CENTRAL FLORIDA ADMINISTRATIVE PROCEDURE

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2018 BUDGET SESSION

PROJET DE LOI ENTITLED. The Medicines (Human and Veterinary) (Bailiwick of Guernsey) Law, 2008 * [CONSOLIDATED TEXT] NOTE

CHAPTER Committee Substitute for House Bill No. 1143

Summary of 2017 Arkansas Legislation Involving the Arkansas Medical Marijuana Amendment of 2016

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled. House Bill 2355

Referred to Committee on Legislative Operations and Elections. SUMMARY Makes various changes relating to elections. (BDR )

MEDICINES AND RELATED SUBSTANCES AMENDMENT BILL

NC General Statutes - Chapter 90 Article 5D 1

Assembly Bill No. 481 Committee on Ways and Means

Sixty-third Legislative Assembly of North Dakota In Regular Session Commencing Tuesday, January 8, 2013

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

PROPOSED AMENDMENTS TO HOUSE BILL 2355

SECURING EXECUTION OF DOCUMENT BY DECEPTION

Report of the Task Force to Review and Recommend Revisions to the Controlled Substances Act

Second medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines

REPORT TO THE CITY COUNCIL. Discussion of Preferential Parking Permit Program

Miss. Code Ann MISSISSIPPI CODE of ** Current through the 2013 Regular Session and 1st and 2nd Extraordinary Sessions ***

S 2253 S T A T E O F R H O D E I S L A N D

TITLE XXX OCCUPATIONS AND PROFESSIONS

Florida Senate Bill No. CS for SB 1604 Ì141410]Î141410

HOUSE OF REPRESENTATIVES AS REVISED BY THE COMMITTEE ON CRIME PREVENTION, CORRECTIONS & SAFETY ANALYSIS

Texas Medicaid Fraud Prevention Act

HOUSE ENROLLED ACT No. 1148

H. R To amend the Federal Food, Drug, and Cosmetic Act with respect to compounding pharmacies, and for other purposes.

CHAPTER Committee Substitute for Senate Bill No. 160

Telephone Consumer Protection Act Proposed Amendments by TRACED Act 47 U.S.C.A Restrictions on use of telephone equipment

Florida Senate CS for SB 448. By the Committee on Environmental Preservation and Conservation; and Senators Dean and Simpson

PHARMACY AND DRUG ACT

2ND SESSION, 41ST LEGISLATURE, ONTARIO 66 ELIZABETH II, Bill 87. (Chapter 11 of the Statutes of Ontario, 2017)

CHAPTER 34:02 ANTIBIOTICS ACT ARRANGEMENT OF SECTIONS

CHAPTER Committee Substitute for Senate Bill No. 1088

Title 6: AERONAUTICS

CHAPTER Committee Substitute for Committee Substitute for Committee Substitute for House Bill No. 183

Assembly Bill No. 19 Assemblymen Parks and Hardy CHAPTER...

BELIZE ANTIBIOTICS ACT CHAPTER 33 REVISED EDITION 2000 SHOWING THE LAW AS AT 31ST DECEMBER, 2000

RULES OF TENNESSEE DEPARTMENT OF ENVIRONMENT AND CONSERVATION CHAPTER ELECTRONIC REPORTING TABLE OF CONTENTS

CHAPTER Committee Substitute for Committee Substitute for House Bill No. 807

The Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005

MISSISSIPPI LEGISLATURE REGULAR SESSION 2018

CHAPTER Committee Substitute for House Bill No. 1277

CHAPTER Committee Substitute for Council Substitute for House Bill No. 105

SENATE BILL No AMENDED IN SENATE MAY 27, 2014 AMENDED IN SENATE APRIL 21, 2014 AMENDED IN SENATE APRIL 1, 2014

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540 X 12 QUALIFIED ALABAMA CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE (QACSC)

House Bill 2355 Ordered by the House April 5 Including House Amendments dated April 5

NC General Statutes - Chapter 163A Article 21 1

HOUSE BILL 1040 A BILL ENTITLED. Maryland Compassionate Use Act

AN ORDINANCE OF THE CITY OF LA HABRA, CALIFORNIA REPEALING AND REPLACING SECTIONS AND OF CHAPTER 18.

CHAPTER Committee Substitute for Senate Bill No. 26-A

INDEPENDENT SALES ASSOCIATE AGREEMENT

State Monitoring of Prescription Drugs and Methamphetamine Precursors Bill Status Update October 2008

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 S 2 SENATE BILL 824 Second Edition Engrossed 11/29/18

The Pharmacy and Pharmacy Disciplines Act

TITLE 15 LEGISLATIVE RULE BOARD OF PHARMACY SERIES 2 RULES OF THE BOARD OF PHARMACY FOR THE UNIFORM CONTROLLED SUBSTANCES ACT

THE NATIONAL DRUG POLICY AND AUTHORITY STATUE, ARRANGEMENT OF SECTIONS. PART I-PRELIMINARY PROVISIONS. Section. 1. Short title. 2.

Transcription:

By Senator Saunders 1 A bill to be entitled 2 An act relating to controlled substances; 3 creating s. 831.311, F.S.; prohibiting the 4 sale, manufacture, alteration, delivery, 5 uttering, or possession of 6 counterfeit-resistant prescription blanks for 7 controlled substances; providing penalties; 8 amending s. 893.04, F.S.; providing additional 9 requirements for the dispensing of a controlled 10 substance listed in Schedule II, Schedule III, 11 or Schedule IV; providing rulemaking authority 12 to the Board of Pharmacy; specifying 13 circumstances under which a pharmacist who 14 dispenses controlled substances by mail is 15 exempt from certain requirements governing 16 patient identification; providing requirements 17 and limitations for dispensing controlled 18 substances upon an oral prescription; creating 19 s. 893.055, F.S.; providing a definition; 20 requiring the Department of Health to establish 21 an electronic system to monitor the prescribing 22 of controlled substances listed in Schedule II, 23 Schedule III, or Schedule IV; requiring the 24 dispensing of such controlled substances to be 25 reported through the system; providing 26 exceptions; providing reporting requirements; 27 providing penalties; requiring that the 28 department and regulatory boards adopt rules; 29 requiring the department to cover all costs for 30 the system; providing for annual 31 appropriations, subject to availability of 1

1 funds; prohibiting using funds from the Medical 2 Quality Assurance Trust Fund to administer the 3 program; creating s. 893.065, F.S.; requiring 4 the department to develop and adopt by rule the 5 form and content for a counterfeit-proof 6 prescription blank for voluntary use by 7 physicians in prescribing a controlled 8 substance listed in Schedule II, Schedule III, 9 or Schedule IV; providing an appropriation and 10 authorizing additional positions; providing for 11 the contingent applicability of penalties; 12 providing contingent effective dates. 13 14 Be It Enacted by the Legislature of the State of Florida: 15 16 Section 1. Section 831.311, Florida Statutes, is 17 created to read: 18 831.311 Unlawful sale, manufacture, alteration, 19 delivery, uttering, or possession of counterfeit-resistant 20 prescription blanks for controlled substances listed in 21 Schedules II, III, and IV.-- 22 (1) It is unlawful for any person having the intent to 23 injure or defraud any person or to facilitate any violation of 24 s. 893.13 to sell, manufacture, alter, deliver, utter, or 25 possess any counterfeit-resistant prescription blanks for 26 controlled substances, the form and content of which are 27 adopted by rule of the Department of Health pursuant to s. 28 893.065. 29 (2) Any person who violates this section commits a 30 felony of the third degree, punishable as provided in s. 31 775.082, s. 775.083, or s. 775.084. 2

1 Section 2. Section 893.04, Florida Statutes, is 2 amended to read: 3 893.04 Pharmacist and practitioner.-- 4 (1) A pharmacist, in good faith and in the course of 5 professional practice only, may dispense controlled substances 6 upon a written or oral prescription of a practitioner, under 7 the following conditions: 8 (a) Oral prescriptions must be promptly reduced to 9 writing by the pharmacist or recorded electronically if 10 permitted by federal law. 11 (b) The written prescription must be dated and signed 12 by the prescribing practitioner on the day when issued. 13 (c) There shall appear on the face of the prescription 14 or written record thereof for the controlled substance the 15 following information: 16 1. The full name and address of the person for whom, 17 or the owner of the animal for which, the controlled substance 18 is dispensed. 19 2. The full name and address of the prescribing 20 practitioner and the practitioner's federal controlled 21 substance registry number shall be printed thereon. 22 3. If the prescription is for an animal, the species 23 of animal for which the controlled substance is prescribed. 24 4. The name of the controlled substance prescribed and 25 the strength, quantity, and directions for use thereof. 26 5. The number of the prescription, as recorded in the 27 prescription files of the pharmacy in which it is filled. 28 6. The initials of the pharmacist filling the 29 prescription and the date filled. 30 31 3

1 (d) The prescription shall be retained on file by the 2 proprietor of the pharmacy in which it is filled for a period 3 of 2 years. 4 (e) Affixed to the original container in which a 5 controlled substance is delivered upon a prescription or 6 authorized refill thereof, as hereinafter provided, there 7 shall be a label bearing the following information: 8 1. The name and address of the pharmacy from which 9 such controlled substance was dispensed. 10 2. The date on which the prescription for such 11 controlled substance was filled. 12 3. The number of such prescription, as recorded in the 13 prescription files of the pharmacy in which it is filled. 14 4. The name of the prescribing practitioner. 15 5. The name of the patient for whom, or of the owner 16 and species of the animal for which, the controlled substance 17 is prescribed. 18 6. The directions for the use of the controlled 19 substance prescribed in the prescription. 20 7. A clear, concise warning that it is a crime to 21 transfer the controlled substance to any person other than the 22 patient for whom prescribed. 23 (f) A prescription for a controlled substance listed 24 in Schedule II may be dispensed only upon a written 25 prescription of a practitioner, except that in an emergency 26 situation, as defined by regulation of the Department of 27 Health, such controlled substance may be dispensed upon oral 28 prescription but is limited to a 72-hour supply. A No 29 prescription for a controlled substance listed in Schedule II 30 may not be refilled. 31 4

1 (g) A No prescription for a controlled substance 2 listed in Schedule Schedules III, Schedule IV, or Schedule V 3 may not be filled or refilled more than five times within a 4 period of 6 months after the date on which the prescription 5 was written unless the prescription is renewed by a 6 practitioner. 7 (2)(a) A pharmacist may not dispense a controlled 8 substance listed in Schedule II, Schedule III, or Schedule IV 9 to any patient or patient's agent without first determining, 10 in the exercise of her or his professional judgment, that the 11 order is valid. The pharmacist or pharmacist's agent shall 12 obtain a government-issued identification card or other form 13 of documentary identification substantiating the identity of a 14 patient or patient's agent before dispensing to such patient 15 or patient's agent any controlled substance listed in Schedule 16 II, Schedule III, or Schedule IV. The pharmacist or 17 pharmacist's agent shall make a record of the type of 18 documentary identification provided by the patient or 19 patient's agent. If the patient or patient's agent does not 20 have appropriate identification, the pharmacist may dispense 21 the controlled substance only when the pharmacist determines, 22 in the exercise of her or his professional judgment, that the 23 order is valid and includes such information in the patient's 24 record. The Board of Pharmacy may adopt, by rule, the 25 patient-identification information required for dispensing 26 controlled substances and procedures by which a pharmacist may 27 verify the validity of a prescription for controlled 28 substances in circumstances in which the required 29 identification information is not provided to the pharmacist. 30 (b) Any pharmacist who dispenses by mail a controlled 31 substance listed in Schedule II, Schedule III, or Schedule IV 5

1 is exempt from the requirement to obtain suitable 2 identification for the prescription dispensed by mail if the 3 pharmacist has obtained the patient's identification through 4 the patient's prescription benefit plan. 5 (c) Any controlled substance listed in Schedule III or 6 Schedule IV may be dispensed by a pharmacist upon an oral 7 prescription if, before filling the prescription, the 8 pharmacist reduces it to writing or records the prescription 9 electronically if permitted by federal law. Such prescriptions 10 must contain the date of the oral authorization. 11 (d) Each written prescription prescribed by a 12 practitioner in this state for a controlled substance listed 13 in Schedule II, Schedule III, or Schedule IV must include both 14 a written and a numerical notation of the quantity on the face 15 of the prescription and a notation of the date, with the 16 abbreviated month written out on the face of the prescription. 17 A pharmacist may, upon verification by the prescriber, 18 document any information required by this paragraph. 19 (e) A pharmacist may not dispense more than a 30-day 20 supply of a controlled substance listed in Schedule III upon 21 an oral prescription issued in this state. 22 (f) A pharmacist may not knowingly fill a prescription 23 that has been forged for a controlled substance listed in 24 Schedule II, Schedule III, or Schedule IV. 25 (3)(2) Notwithstanding the provisions of subsection 26 (1), a pharmacist may dispense a one-time emergency refill of 27 up to a 72-hour supply of the prescribed medication for any 28 medicinal drug other than a medicinal drug listed in Schedule 29 II, in compliance with the provisions of s. 465.0275. 30 (4)(3) The legal owner of any stock of controlled 31 substances in a pharmacy, upon discontinuance of dealing in 6

1 controlled substances, may sell said stock to a manufacturer, 2 wholesaler, or pharmacy. Such controlled substances may be 3 sold only upon an order form, when such an order form is 4 required for sale by the drug abuse laws of the United States 5 or this state, or regulations pursuant thereto. 6 Section 3. Section 893.055, Florida Statutes, is 7 created to read: 8 893.055 Electronic-monitoring system for prescription 9 of controlled substances listed in Schedule II, Schedule III, 10 or Schedule IV.-- 11 (1) As used in this section, the term "pharmacy" means 12 any pharmacy subject to licensure or regulation by the 13 Department of Health pursuant to chapter 465 which dispenses 14 or delivers a controlled substance included on Schedule II, 15 Schedule III, or Schedule IV to a patient in this state. 16 (2) By June 30, 2008, the Department of Health shall 17 design and establish an electronic system consistent with 18 standards of the American Society for Automation in Pharmacy 19 to monitor the prescribing and dispensing of controlled 20 substances listed in Schedule II, Schedule III, or Schedule IV 21 by health care practitioners within the state and the 22 dispensing of such controlled substances to an individual at a 23 specific address within the state by a pharmacy permitted or 24 registered by the Board of Pharmacy. 25 (3) Each time a controlled substance listed in 26 Schedule II, Schedule III, or Schedule IV is dispensed to an 27 individual in this state, the controlled substance must be 28 reported to the Department of Health through the system as 29 soon thereafter as possible, but not more than 35 days after 30 the date the controlled substance is dispensed. A pharmacy or 31 dispensing practitioner may meet the reporting requirements of 7

1 this section by providing to the Department of Health in 2 written or any electronic or magnetic format, including, but 3 not limited to, electronic submission via the Internet or 4 magnetic disc or tape, each controlled substance listed in 5 Schedule II, Schedule III, or Schedule IV which it dispenses. 6 (4) This section does not apply to controlled 7 substances: 8 (a) Administered by a health care practitioner 9 directly to a patient. 10 (b) Dispensed by a health care practitioner authorized 11 to prescribe controlled substances directly to a patient and 12 limited to an amount adequate to treat the patient for a 13 period of not more than 72 hours. 14 (c) Dispensed by a health care practitioner or a 15 pharmacist to an inpatient of a facility that holds an 16 institutional pharmacy permit. 17 (d) Ordered from an institutional pharmacy permitted 18 under s. 465.019 in accordance with the institutional policy 19 for such controlled substances or drugs. 20 (e) Dispensed by a pharmacist or administered by a 21 health care practitioner to a patient or resident receiving 22 care from a hospital, nursing home, assisted living facility, 23 home health agency, hospice, or intermediate care facility for 24 the developmentally disabled which is licensed in this state. 25 (f) Prescribed by a health care practitioner for a 26 patient younger than 16 years of age. 27 (5) The data required to be reported under this 28 section shall be determined by the Department of Health by 29 rule but may include any data required under s. 893.04. 30 (6) A practitioner or pharmacist who dispenses a 31 controlled substance under this section must submit the 8

1 information required by this section in an electronic or other 2 format approved by rule of the Department of Health. The cost 3 to the dispenser in submitting the information required by 4 this section may not be material or extraordinary. Costs not 5 considered to be material or extraordinary include, but are 6 not limited to, regular postage, compact discs, zip-drive 7 storage, regular electronic mail, magnetic tapes, diskettes, 8 and facsimile charges. The information submitted to the 9 Department of Health under this section may be transmitted to 10 any person or agency authorized to receive it pursuant to 11 section 1 of Senate Bill, or similar legislation, and 12 that person or agency may maintain the information received 13 for up to 24 months before purging the information from its 14 records. All transmissions required by this subsection must 15 comply with relevant privacy and security laws of the state 16 and Federal Government. However, any authorized agency 17 receiving such information may maintain it for longer than 24 18 months if the information is pertinent to an ongoing 19 investigation or prosecution. 20 (7) Any person who knowingly fails to report the 21 dispensing of a controlled substance listed in Schedule II, 22 Schedule III, or Schedule IV as required by this section 23 commits a misdemeanor of the first degree, punishable as 24 provided in s. 775.082 or s. 775.083. 25 (8) The Department of Health and the regulatory boards 26 for the health care practitioners subject to this section 27 shall adopt rules pursuant to ss. 120.536(1) and 120.54 to 28 administer this section. 29 (9) All costs incurred by the Department of Health in 30 administering the prescription-monitoring system shall be 31 borne by the department, and an amount necessary to cover such 9

1 costs shall be appropriated annually, subject to the 2 availability of funds, from the Grants and Donations Trust 3 Fund. The Medical Quality Assurance Trust Fund may not be used 4 to administer or otherwise fund this program. 5 Section 4. Section 893.065, Florida Statutes, is 6 created to read: 7 893.065 Counterfeit-resistant prescription blanks for 8 controlled substances listed in Schedule II, Schedule III, or 9 Schedule IV.--The Department of Health shall develop and adopt 10 by rule the form and content for a counterfeit-resistant 11 prescription blank which may be used by practitioners for the 12 purpose of prescribing a controlled substance listed in 13 Schedule II, Schedule III, or Schedule IV. The Department of 14 Health may require the prescription blanks to be printed on 15 distinctive, watermarked paper and to bear the preprinted 16 name, address, and category of professional licensure of the 17 practitioner and that practitioner's federal registry number 18 for controlled substances. The prescription blanks may not be 19 transferred. 20 Section 5. The sum of $2,564,670 in recurring general 21 revenue funds and $1,837,677 in nonrecurring general revenue 22 funds are appropriated to the Department of Health to 23 implement the provisions of this bill. Three additional 24 full-time equivalent positions are authorized for the 25 2007-2008 fiscal year to implement the provisions of ss. 26 893.055 and 893.065, Florida Statutes, as created by this act. 27 Section 6. The penalties created in ss. 831.311(2) and 28 893.055(7), Florida Statutes, by this act shall take effect 29 only upon the adoption by the Department of Health and each 30 applicable professional regulatory board of the rules required 31 10

1 pursuant to ss. 893.055(8) and 893.065, Florida Statutes, as 2 created by this act. 3 Section 7. Except as otherwise expressly provided in 4 this act, this act shall take effect July 1, 2007, if Senate 5 Bill, or similar legislation, is adopted in the same 6 legislative session or an extension thereof and becomes law. 7 8 ***************************************** 9 SENATE SUMMARY 10 Prohibits the sale, manufacture, alteration, delivery, uttering, or possession of counterfeit-resistant 11 prescription blanks for controlled substances. Provides additional requirements for the dispensing of a 12 controlled substance listed in Schedule II, Schedule III, or Schedule IV. Requires the Department of Health to 13 establish an electronic system to monitor the prescribing of controlled substances listed in Schedule II, Schedule 14 III, or Schedule IV. Requires the dispensing of such controlled substances to be reported through the system. 15 Requires that the department and regulatory boards adopt rules. Requires the department to cover all costs for the 16 system. Prohibits using funds from the Medical Quality Assurance Trust Fund to administer the program. Requires 17 the department to develop and adopt by rule the form and content for a counterfeit-proof prescription blank for 18 voluntary use by physicians in prescribing a controlled substance listed in Schedule II, Schedule III, or 19 Schedule IV. 20 21 22 23 24 25 26 27 28 29 30 31 11